Clinical trials: Pancreatic Exocrine Neoplasm
Bone Marrow Failure Syndrome, Congenital Amegakaryocytic Thrombocytopenia
Treosulfan-Based Conditioning Regimen Before a Blood or Bone Marrow Transplant for the Treatment of Bone Marrow Failure Diseases (BMT CTN 1904)
This phase II trial tests whether treosulfan, fludarabine, and rabbit antithymocyte globulin (rATG) work when given before a blood or bone marrow transplant (conditioning regimen) to cause fewer complications for patients with…
- Conditions
- Bone Marrow Failure Syndrome, Congenital Amegakaryocytic Thrombocytopenia, Diamond-Blackfan Anemia, Hereditary Sideroblastic Anemia
- Trial name
- NCT04965597
- Testing
- Treosulfan, Fludarabine Phosphate, Tacrolimus
- Where
- 24 sites in United States
- Volunteers
- 40 people
- Sponsor
- Fred Hutchinson Cancer Center
Soft Tissue Sarcoma, Colorectal Cancer
A Safety Study of SGN-CD47M in Patients With Solid Tumors
This trial will study SGN-CD47M to find out whether it is an effective treatment for different types of solid tumors and what side effects (unwanted effects) may occur. The study will have two parts.
- Conditions
- Soft Tissue Sarcoma, Colorectal Cancer, Head and Neck Squamous Cell Carcinoma, Non-small Cell Lung Carcinoma
- Trial name
- NCT03957096
- Testing
- SGN-CD47M
- Where
- 5 sites in United States
- Volunteers
- 16 people
- Sponsor
- Seagen Inc.
Exocrine Pancreatic Insufficiency, Acute Pancreatitis
Pancreatic Exocrine Insufficiency in Acute Pancreatitis
Severe pancreatitis induces more damage in the pancreas and might therefore result reduced exocrine function leading to the insufficiency.
- Trial name
- APPEI (NCT02563080)
- Where
- Finland
- Volunteers
- 50 people
- Sponsor
- Helsinki University Central Hospital
Chronic Pancreatitis, Inflammatory Bowel Diseases
Genomic Resources for Enhancing Available Therapies (GREAT1.0) Study
This is a prospective, descriptive, observational research study designed to observe and document the clinical practice by domain experts, and how the knowledge of new findings that are published in the medical literature affect…
- Conditions
- Chronic Pancreatitis, Inflammatory Bowel Diseases, Hepatitis, NASH - Nonalcoholic Steatohepatitis
- Trial name
- GREAT1 (NCT04306939)
- Testing
- venipuncture, Questionnaires, Additional Sample Collections
- Where
- United States
- Volunteers
- 120,000 people, healthy volunteers welcome
- Sponsor
- University of Pittsburgh
Pancreatic Cancer
Secretin-enhanced Magnetic Resonance Cholangiopancreatography (S-MRCP) and Pancreatic Function Following Surgery
The aim of this study will be to determine whether secretin-enhanced MRCP (S-MRCP) as well as traditional magnetic resonance imaging (MRI) of the pancreas will allow the investigators to quantify the pancreas' ability to secrete…
- Trial name
- NCT01094535
- Testing
- Synthetic Human Secretin
- Where
- United States
- Sponsor
- Columbia University
Nonalcoholic Fatty Liver Disease After Pancreaticoduodenectomy
The Impact of Hepatic Steatosis on Survival After Pancreaticoduodenectomy
We will use simple summaries, educational handouts, and discussions with doctors and nurses to explain this study. The study looks at patients with early-stage pancreatic cancer who undergo pancreaticoduodenectomy (Whipple…
- Trial name
- NCT07182136
- Testing
- Pancreaticoduodenectomy
- Volunteers
- 200 people
- Sponsor
- Wei-Hsun Lu
Chronic Myeloid Leukemia (CML), Acute Myelogenous Leukemia (AML)
CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant
The purpose of this study is to learn more about the effects of (classification determinant) CD34+ stem cell selection on graft versus host disease (GVHD) in children, adolescents, and young adults.
- Conditions
- Chronic Myeloid Leukemia (CML), Acute Myelogenous Leukemia (AML), Myelodysplastic Syndrome (MDS), Juvenile Myelomonocytic Leukemia (JMML)
- Trial name
- NCT02061800
- Testing
- CliniMACS CD34+ Reagent System, Thiotepa, Cyclophosphamide
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Diane George
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Leukemia in Remission
Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer
This phase II trial studies how well fludarabine phosphate, cyclophosphamide, total body irradiation, and donor stem cell transplant work in treating patients with blood cancer.
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Leukemia in Remission, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
- Trial name
- NCT03333486
- Testing
- Cyclophosphamide, Fludarabine Phosphate, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Roswell Park Cancer Institute
Exocrine Pancreatic Insufficiency (EPI)
A Study of Creon (Pancrelipase) in Resected and Non-resected Pancreatic Cancer Participants With Exocrine Pancreatic Insufficiency (EPI)
This is a study in participants with Exocrine Pancreatic Insufficiency (EPI) due to pancreatic cancer. This study will include resected participants who are post pancreatic cancer surgery, and an additional cohort in non-resected…
- Trial name
- NCT03859869
- Testing
- Pancrelipase
- Where
- 33 sites in United States
- Volunteers
- 1 people
- Sponsor
- AbbVie
Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
This trial will look at a drug called sigvotatug vedotin (SGN-B6A) alone and with pembrolizumab, with or without chemotherapy, to find out whether it is safe for people who have solid tumors.
- Conditions
- Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck, HER2 Negative Breast Neoplasms, Esophageal Squamous Cell Carcinoma
- Trial name
- NCT04389632
- Testing
- sigvotatug vedotin, pembrolizumab, cisplatin
- Where
- 158 sites in United States, France and 5 more
- Volunteers
- 1,006 people
- Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
Cancer
The FOCCUS Study: "Focusing on Cancers Chemotherapys' Untreated Symptoms"
The aim of the study is to identify how often gastrointestinal problems interfere with quality of life as a result of treatment for cancer with chemotherapy.
- Trial name
- FOCCUS (NCT02121626)
- Where
- United Kingdom
- Volunteers
- 248 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Intraductal Papillary Mucinous Neoplasms, Pancreatic Exocrine Insufficiency
IPEX Study: Pancreatic Exocrine Insufficiency as a Functional Marker of Disease Progression in Patients With IPMN
Intraductal Papillary Mucinous Neoplasms (IPMN) are pancreatic cystic neoplasms managed through imaging-based surveillance focused on oncologic risk.
- Trial name
- IPEX (NCT07535125)
- Volunteers
- 600 people
- Sponsor
- A.O.U. Città della Salute e della Scienza
Congenital Adrenal Hyperplasia, Familial Hyperinsulinemic Hypoglycemia 1
Baby Detect : Genomic Newborn Screening
Newborn screening (NBS) is a global initiative of systematic testing at birth to identify babies with pre-defined severe but treatable conditions.
- Conditions
- Congenital Adrenal Hyperplasia, Familial Hyperinsulinemic Hypoglycemia 1, Phosphoglucomutase 1 Deficiency, Maturity Onset Diabetes of the Young
- Trial name
- BabyDetect (NCT05687474)
- Where
- Belgium
- Volunteers
- 6,824 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire de Liege
Adenocarcinoma of the Pancreas, Normal Pancreatic Exocrine Function
Pancreatic Enzyme Suppletion in Pancreatic Cancer
This study will evaluate the effect of immediate pancreatic enzyme suppletion on the physical and mental health status and survival of patients who are diagnosed with pancreatic cancer and are highly likely to develop exocrine…
- Trial name
- EPC (NCT01401387)
- Testing
- Timing of start treatment with pancreatic enzymes
- Where
- Netherlands
- Sponsor
- Foundation for Liver Research
Shwachman-Diamond Syndrome, SDS
Shwachman-Diamond Syndrome Global Patient Survey and Partnering Platform
The Shwachman-Diamond Syndrome Global Patient Survey and Collaboration Program (SDS-GPS) is an opportunity for patients and their families - from anywhere in the world - to share their experience living with SDS via a safe…
- Conditions
- Shwachman-Diamond Syndrome, SDS, IBMF, Congenital Neutropenia
- Trial name
- SDS-GPS (NCT06999954)
- Where
- United States
- Volunteers
- 8,000 people
- Sponsor
- Shwachman-Diamond Syndrome Alliance Inc
Adenocarcinoma of the Pancreas, Adenocarcinoma of the Colon
Pembrolizumab In Combination With Debio 1143 In Pancreatic and Colorectal Advanced/Metastatic Adenocarcinoma
This trial is a Phase I study to be conducted in patients with non-MSI-high advanced/metastatic pancreatic ductal adenocarcinoma (PDAC) or colorectal cancer (CRC) and is divided in two Parts.
- Conditions
- Adenocarcinoma of the Pancreas, Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum
- Trial name
- CATRIPCA (NCT03871959)
- Testing
- Pembrolizumab, DEBIO1143
- Where
- France
- Volunteers
- 54 people
- Sponsor
- Centre Leon Berard
Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma
CEND-1 in Combination With Nabpaclitaxel and Gemcitabine in Metastatic Pancreatic Cancer
CEND-1, Gemicitabine and Nab-Paclitaxel for Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT03517176
- Testing
- CEND-1, Nab-paclitaxel, Gemcitabine
- Where
- 3 sites in Australia
- Volunteers
- 30 people
- Sponsor
- Lisata Therapeutics, Inc.
Focus of Study Instead
Afatinib as Cancer Therapy for Exocrine Pancreatic Tumours
Single-agent gemcitabine is currently still regarded as one international standard of care for patients with advanced pancreatic cancer (Burris 1997 [4]).
- Trial name
- ACCEPT (NCT01728818)
- Testing
- Gemcitabine, Afatinib
- Where
- Germany
- Volunteers
- 119 people
- Sponsor
- PD Dr. med. Volker Heinemann
Pancreatic Adenocarcinoma
Reorganization of the Healthcare System During COVID-19 Pandemic: Impact on Management of Patients With Exocrine Pancreatic Cancer
Pancreatic adenocarcinoma will be the 2nd cause of death by cancer in Europe in 2030. Pancreatic adenocarcinoma has poor prognosis with an all-stages combined 5-year survival rate below 8%.
- Trial name
- CAPANCOVID-19 (NCT04406571)
- Testing
- Data record
- Where
- France
- Volunteers
- 700 people
- Sponsor
- CHU de Reims
Exocrine Pancreatic Cancer
High Dose Omeprazole in Patients With Pancreatic Cancer
The purpose of this study is to test the safety of high dose omeprazole and see what effects that it has on patients with exocrine pancreatic cancer.
- Trial name
- OU202005AJ (NCT04930991)
- Testing
- Omeprazole
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Oklahoma